Bigger Payloads. Broader Possibilities.

Icosphere Biosciences is pioneering the next generation of therapies using precision virus-like particles (VLPs). Built on science, designed for scale, and focused on the future.

PRECISION THERAPEUTICS

Diseases requiring the delivery of large DNA molecules remain untreated. Our proprietary platform enables scalable, high-efficiency VLP production, unlocking the delivery of DNA molecules of over 30Kb.

We're helping to improve clinical outcomes.

We are currently advancing a pipeline of safe, customizable VLPs for conditions with urgent unmet clinical needs in gene supplementation and cancer immunotherapy.

WHO WE ARE

Founded in Oxford, Icosphere Biosciences combines deep expertise in molecular virology and bioprocess development to create transformative therapies for patients suffering from difficult-to-treat diseases.

Our mission:

To develop and deliver scalable, safe, and targeted VLPs that fulfil the promise of genomic medicine.

We are a multidisciplinary team of scientists at the forefront of translational science, collaborating with academic and clinical partners to move boldly from bench to bedside.

Our Technology

The Power of Virus-Like Particles

Virus-like particles (VLPs) are nanoscale structures that mimic the shape and size of viruses but have no viral genes, making them non-infectious and safe for therapeutic use.

Their unique architecture allows for:

  • Highly efficient cell entry
  • Targeted delivery of therapeutic payloads
  • Immunomodulatory properties

Our Proprietary VLP Platform

At the core of our company is a scalable, proprietary manufacturing technology that overcomes historical barriers in producing pure VLPs.

High-yield, consistent output

Perfect for clinical and commercial use.

Enhanced biostability

To maximize therapeutic efficacy.

Plug-and-play

Adaptable to diverse therapeutic payloads.

Why VLPs? Why Now?

Traditional drug delivery systems lack the precision, biocompatibility, and adaptability required for next-generation therapies.

Our VLPs bridge that gap — offering a versatile, scalable, and safe platform suited to today’s most urgent therapeutic challenges.